Udenafil
Clinical data | |
---|---|
ATC code | G04BE11 (WHO) |
Pharmacokinetic data | |
Biological half-life | 7.3–12.1 hours |
Identifiers | |
| |
CAS Number | 268203-93-6 |
PubChem (CID) | 6918523 |
DrugBank | DB06267 |
ChemSpider | 5293720 |
UNII | L5IB4XLY36 |
KEGG | D10027 |
Chemical and physical data | |
Formula | C25H36N6O4S |
Molar mass | 516.657 g/mol |
3D model (Jmol) | Interactive image |
| |
| |
(what is this?) (verify) |
The drug udenafil, marketed under the trade name Zydena, is within the PDE5-inhibitor class (which also includes avanafil, sildenafil, tadalafil, and vardenafil). Used, like other PDE5 inhibitors, to treat erectile dysfunction, undenafil was developed by Dong-A Pharmaceutical.[1] With action of fairly rapid onset (peak plasma concentration after 1 to 1.5 hours) yet long duration (plasma half life of 11 to 13 hours), udenafil's pharmacokinetics allows once-daily dosage (in addition to on-demand use).[2] Typical doses are 100 and 200 mg. Udenafil is available in Korea, Russia, and the Philippines;[3] in the United States, it has not been approved by the U.S. Food and Drug Administration.
References
- ↑ Zydena (udenafil) product-information page. Dong-A Pharmaceutical. Retrieved on April 13, 2009.
- ↑ "Udenafil: Efficacy and tolerability in the management of erectile dysfunction".
- ↑ [http://www.drugs.com/international/zydena.html "Zydena", Drugs.com
This article is issued from Wikipedia - version of the 4/17/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.